S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs

Microbot Medical (MBOT) Earnings Date, Estimates & Call Transcripts

$1.36
-0.02 (-1.45%)
(As of 11/27/2023 ET)
Compare
Today's Range
$1.33
▼
$1.40
50-Day Range
$1.13
▼
$1.64
52-Week Range
$1.00
▼
$4.65
Volume
42,809 shs
Average Volume
54,910 shs
Market Capitalization
$15.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

MBOT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

MBOT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Microbot Medical Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20231($0.45)($0.45)($0.45)
Q2 20231($0.31)($0.31)($0.31)
Q3 20231($0.28)($0.28)($0.28)
Q4 20231($0.28)($0.28)($0.28)
FY 20234($1.32)($1.32)($1.32)
Q1 20241($0.20)($0.20)($0.20)
Q2 20241($0.16)($0.16)($0.16)
Q3 20241($0.16)($0.16)($0.16)
Q4 20241($0.16)($0.16)($0.16)
FY 20244($0.68)($0.68)($0.68)

Microbot Medical Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/14/2023Q2 2023($0.31)($0.25)+$0.06($0.25)--
5/17/2023Q1 2023($0.45)($0.36)+$0.09($0.36)--
3/31/2023Q4 2022-($0.38)($0.38)($0.38)--
11/14/2022Q3 2022($0.51)($0.49)+$0.02($0.49)--
8/15/2022Q2 2022($0.45)($0.49)($0.04)($0.49)--
5/16/2022Q1 2022-($0.45)($0.45)($0.45)--
3/31/2022Q4 2021-($0.54)($0.54)($0.54)--
11/15/2021Q3($0.36)($0.36)-($0.36)--
8/16/2021Q2 2021($0.35)($0.35)-($0.35)--
5/17/2021Q1 2021($0.33)($0.34)($0.01)($0.34)--
3/31/2021Q4 2020-($0.37)($0.37)($0.37)--












Microbot Medical Earnings - Frequently Asked Questions

How much profit does Microbot Medical generate each year?

Microbot Medical (NASDAQ:MBOT) has a recorded net income of -$13.17 million. MBOT has generated -$1.48 earnings per share over the last four quarters.

What is Microbot Medical's EPS forecast for next year?

Microbot Medical's earnings are expected to grow from ($1.09) per share to ($0.64) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:MBOT) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -